Cartesian Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNAC Nasdaq 2836 www.cartesiantherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cartesian Therapeutics, Inc.

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - May 13th, 2025 11:00 am
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - May 11th, 2025 12:56 pm
Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations - May 10th, 2025 12:52 pm
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - May 8th, 2025 11:00 am
Cartesian Therapeutics Announces New Employment Inducement Grants - May 2nd, 2025 11:05 am
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - Apr 8th, 2025 11:00 am
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Apr 1st, 2025 11:00 am
Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Mar 23rd, 2025 12:30 pm
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Mar 14th, 2025 4:15 pm
Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Mar 14th, 2025 10:13 am
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - Mar 13th, 2025 11:00 am
Cartesian Therapeutics Announces New Employment Inducement Grant - Mar 6th, 2025 12:05 pm
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Feb 18th, 2025 12:00 pm
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - Jan 27th, 2025 12:00 pm
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases - Jan 13th, 2025 12:00 pm
Cartesian Therapeutics initiated with a Buy at BTIG - Dec 20th, 2024 11:50 am
Cartesian Therapeutics Reports Promising Phase 2b Trial Results - Dec 4th, 2024 11:33 am
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial - Dec 3rd, 2024 11:00 am
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - Nov 21st, 2024 12:00 pm
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Nov 21st, 2024 10:15 am